Mirvie RNA test aims to predict pregnancy complications

Researchers developed machine learning models capable of predicting metabolic syndrome 2 to 7 years postpartum, using factors such as blood pressure, cholesterol, and stress levels.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Pregnant women infected with avian influenza face a 90% maternal and 86% infant mortality rate, underscoring the urgent need for pandemic preparedness and protection strategies.